Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Clene Inc. reports promising progress on its CNM-Au8 therapy for ALS, with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway, supported by significant survival data and reduced expenses.
Clene Inc. announced promising developments in its neurological disease treatment program, highlighting significant progress for its investigational therapy CNM-Au8 in addressing amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
The biopharmaceutical company is preparing to submit a New Drug Application (NDA) under the FDA's Accelerated Approval pathway in the fourth quarter of 2025. This potential milestone is supported by compelling survival data demonstrating CNM-Au8's effectiveness, particularly in patients with more severe ALS.
New research results indicate that CNM-Au8 significantly improved survival rates for ALS patients. Additionally, the company presented Phase 2 extension results for multiple sclerosis, showcasing promising evidence of remyelination and neuronal repair.
Financially, Clene reported a reduced net loss of $0.8 million for the first quarter, with $9.8 million in cash reserves sufficient to fund operations through the third quarter of 2025. These financial metrics suggest strategic cost management and efficient resource allocation.
The potential FDA approval could represent a critical advancement in neurodegenerative disease treatment, offering hope for patients with limited therapeutic options. CNM-Au8's unique approach targeting mitochondrial function and the NAD pathway while reducing oxidative stress distinguishes it from current treatment modalities.